Elicera Therapeutics AB (publ) (FRA:8E8)

Market Cap	25.68M +143.5%
Revenue (ttm)	1.00M +52.3%
Net Income	-1.61M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	3.83
Dividend	n/a
Ex-Dividend Date	n/a

Volume	250
Average Volume	n/a
Open	0.5080
Previous Close	0.5210
Day's Range	0.5080 - 0.5080
52-Week Range	0.1740 - 0.6860
Beta	n/a
RSI	57.39
Earnings Date	Feb 13, 2026

About Elicera Therapeutics AB

Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 2
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 8E8

Financial Performance

In 2025, Elicera Therapeutics AB's revenue was 10.86 million, an increase of 52.28% compared to the previous year's 7.13 million. Losses were -17.41 million, 8.05% more than in 2024.

Financial numbers in SEK